Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194491 · ClinicalTrials.gov registry record · Phase 1
A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02194491: Completed Phase 1 study, sponsored by Astellas Pharma Global Development.
NCT02194491 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02194491, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a novel PET tracer (\[11C\]AS2471907), and to use \[11C\]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose administration of ASP3662.
Interventions
- RADIATION Positron Emission Tomography (PET)
- OTHER [11C]AS2471907
- DRUG ASP3662
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT02194491 record still lists
NCT02194491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 3 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT02194491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02194491 about?
NCT02194491 is a clinical study titled "A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662". The purpose of this study is to evaluate a novel PET tracer (\[11C\]AS2471907), and to use \[11C\]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose administration of ASP3662.
What is the current status of trial NCT02194491?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02194491?
The interventions under investigation include: Positron Emission Tomography (PET) (RADIATION), [11C]AS2471907 (OTHER), ASP3662 (DRUG).
Who is sponsoring clinical trial NCT02194491?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02194491's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia